Prospective Registry Study of Endovascular Treatment for Acute Ischemic Stroke Patients
Launched by TINGYU-YI · Aug 10, 2023
Trial Information
Current as of July 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into the effectiveness of endovascular treatments for patients who have suffered an acute ischemic stroke, which is a type of stroke caused by a blockage in the blood vessels of the brain. The goal is to better understand how these patients are assessed, diagnosed, and treated using various endovascular techniques, such as removing the blockage or opening narrowed blood vessels. The trial is currently recruiting participants aged 65 and older of any gender who have experienced a stroke and have imaging tests confirming a blockage in a major brain artery.
If you or a loved one are considering participation, you would need to have a confirmed stroke that meets specific criteria, and you must be able to provide informed consent either by signing a document or through emergency procedures. It's important to note that those with bleeding in the brain or other specific conditions may not be eligible. Participants will receive the necessary treatment and follow-ups as part of the study, helping researchers gather valuable information that could improve care for future stroke patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Acute ischemic stroke;
- • 2. Brain imaging confirmed intracranial large vessel occlusion: intracranial internal carotid artery (ICA), middle cerebral artery (MCA M1/M2), anterior cerebral artery (ACA A1/A2), basilar artery (BA), vertebral artery (VA V4), and posterior cerebral artery (PCA P1);
- • 3. Initiation of any type of endovascular treatment, including mechanical thrombectomy, aspiration, angioplasty, and stenting;
- • 4. Informed Consent as documented by signature or fulfilling the criteria for emergency consent/ deferral consent
- Exclusion Criteria:
- • 1. Acute intracranial haemorrhage
- • 2. No evidence of large vessel occlusion on digital subtraction angiography.
- • 3. Patient bedridden or presenting from a nursing home
- • 4. Foreseeable difficulties in follow-up due to geographic reasons (e.g. patients living abroad) -
About Tingyu Yi
Tingyu-yi is a pioneering clinical trial sponsor dedicated to advancing medical research and innovation. With a focus on developing novel therapies and improving patient outcomes, Tingyu-yi collaborates with leading healthcare institutions and researchers to conduct rigorous clinical studies across various therapeutic areas. The organization is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the safety and efficacy of new treatments. Through its comprehensive approach to clinical development, Tingyu-yi aims to contribute significantly to the future of healthcare and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zhangzhou, Fujian, China
Lanzhou, Gansu, China
Jiamusi, Heilongjiang, China
Nanchang, Jiangxi, China
Songyuan, Jilin, China
Shenyang, Liaoning, China
Patients applied
Trial Officials
Wen-huo Chen, bachelor
Principal Investigator
Zhangzhou Affiliated Hospital to Fujian Medical University , Fujian ,China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported